Alternative drug recommendation results in saving over $79,500 for a patient’s treatment.
A physician prescribed Harvoni® once daily for 12 weeks for a 47-year-old male for the treatment of Chronic Hepatitis C Virus (HCV) infection, with a confirmed HCV genotype 1.
Based on the clinical information included with the prior authorization, the IPM clinical pharmacist determined that the patient was equally qualified for another HCV antiviral agent, Mavyret®.
While equally effective as Harvoni® for HCV, Mavyret is less expensive, shortens the course of therapy by four weeks, and resulted in a lower copay for the member. Talk about a win-win! The net result is the savings of over $71,000 for a single patient’s treatment.
|HCV Direct-Acting Anti Viral Agent||Course of Therapy||Total Cost of Therapy|